• 1
    Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999; 53: 193742.
  • 2
    Yaffe K, Lindquist K, Penninx BW et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003; 61: 7680.
  • 3
    Engelhart MJ, Geerlings MI, Meijer J et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol 2004; 61: 66872.
  • 4
    Wright CB, Sacco RL, Rundek TR, Delman JB, Rabbani LE, Elkind MS. Interleukin-6 is associated with cognitive function: the Northern Manhattan Study. J Stroke Cerebrovasc Dis 2006; 15: 348.
  • 5
    Schram MT, Euser SM, de Craen AJ et al. Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc 2007; 55: 70816.
  • 6
    Gimeno D, Marmot MG, Singh-Manoux A. Inflammatory markers and cognitive function in middle-aged adults: the Whitehall II study. Psychoneuroendocrinology 2008; 33: 132234.
  • 7
    Papassotiropoulos A, Hock C, Nitsch RM. Genetics of interleukin 6: implications for Alzheimer's disease. Neurobiol Aging 2001; 22: 86371.
  • 8
    Huth C, Heid IM, Vollmert C et al. IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies. Diabetes 2006; 55: 291521.
  • 9
    Huth C, Illig T, Herder C et al. Joint analysis of individual participants' data from 17 studies on the association of the IL6 variant -174G>C with circulating glucose levels, interleukin-6 levels, and body mass index. Ann Med 2009; 41: 12838.
  • 10
    Dai L, Liu D, Guo H, Wang Y, Bai Y. Association between polymorphism in the promoter region of Interleukin 6 (-174 G/C) and risk of Alzheimer's disease: a meta-analysis. J Neurol 2012; 259: 4149.
  • 11
    Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 162330.
  • 12
    Shepherd J, Blauw GJ, Murphy MB et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 1999; 84: 11927.
  • 13
    Trompet S, van Vliet P, de Craen AJ et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 2010; 257: 8590.
  • 14
    Houx PJ, Shepherd J, Blauw GJ et al. Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk. J Neurol Neurosurg Psychiatry 2002; 73: 3859.
  • 15
    Sattar N, Murray HM, Welsh P et al. Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events? PLoS Med 2009; 6: e1000099.
  • 16
    Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 136976.
  • 17
    Hoshi T, Kitagawa K, Yamagami H, Furukado S, Hougaku H, Hori M. Relations of serum high-sensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke 2005; 36: 76872.
  • 18
    van Exel E, Gussekloo J, Houx P et al. Atherosclerosis and cognitive impairment are linked in the elderly. The Leiden 85-plus Study. Atherosclerosis 2002; 165: 3539.
  • 19
    Campbell IL, Stalder AK, Chiang CS et al. Transgenic models to assess the pathogenic actions of cytokines in the central nervous system. Mol Psychiatry 1997; 2: 1259.
  • 20
    Wilson CJ, Finch CE, Cohen HJ. Cytokines and cognition–the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 2002; 50: 204156.
  • 21
    Naitza S, Porcu E, Steri M et al. A genome-wide association scan on the levels of markers of inflammation in Sardinians reveals associations that underpin its complex regulation. PLoS Genet 2012; 8: e1002480.
  • 22
    Mooijaart SP, Sattar N, Trompet S et al. C-reactive protein and genetic variants and cognitive decline in old age: the PROSPER study. PLoS ONE 2011; 6: e23890.
  • 23
    The Interleukin-6 Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet 2012; 379: e23890.